Warrants of series TO5 were subscribed to approximately 97.4 percent and ExpreS2ion receives approximately SEK 44.3 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SINGAPORE, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, September 22, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion" or the “Company”) today announces the outcome of the exercise of warrants of series TO5, which were issued in connection with the Company’s